Orchestra BioMed Holdings, Inc. (OBIO)

USD 4.76

(-3.64%)

Market Cap (In USD)

180.94 Million

Revenue (In USD)

2.76 Million

Net Income (In USD)

-49.12 Million

Avg. Volume

126.85 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.22-10.44
PE
-
EPS
-
Beta Value
0.409
ISIN
US68572M1062
CUSIP
68572M106
CIK
1814114
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. David P. Hochman
Employee Count
-
Website
https://orchestrabiomed.com
Ipo Date
2020-08-04
Details
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.